Crescent Capital BDC, Inc. (CCAP)
| Market Cap | 433.68M -17.7% |
| Revenue (ttm) | 163.07M -13.8% |
| Net Income | 15.09M -69.5% |
| EPS | 0.41 -69.5% |
| Shares Out | 36.85M |
| PE Ratio | 28.86 |
| Forward PE | 7.86 |
| Dividend | $1.45 (12.32%) |
| Ex-Dividend Date | Aug 31, 2026 |
| Volume | 304,339 |
| Open | 11.75 |
| Previous Close | 11.77 |
| Day's Range | 11.73 - 11.96 |
| 52-Week Range | 10.64 - 16.04 |
| Beta | 0.58 |
| Analysts | Buy |
| Price Target | 13.57 (+15.29%) |
| Earnings Date | Aug 10, 2026 |
About CCAP
Crescent Capital BDC, Inc. is as a business development company is a private debt fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.
Financial Performance
In 2025, Crescent Capital BDC's revenue was $167.29 million, a decrease of -15.24% compared to the previous year's $197.36 million. Earnings were $34.51 million, a decrease of -53.14%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CCAP stock is "Buy." The 12-month stock price target is $13.57, which is an increase of 15.29% from the latest price.
News
Crescent Capital BDC, Inc. Schedules Earnings Release and Conference Call to Discuss its Second Quarter Ended June 30, 2026 Financial Results
LOS ANGELES, July 24, 2026 (GLOBE NEWSWIRE) -- Crescent Capital BDC, Inc. (“Crescent BDC”) (NASDAQ: CCAP) today announced it will release its financial results for the second quarter ended June 30, 20...
Crescent Capital BDC price target lowered to $13 from $15 at Keefe Bruyette
Keefe Bruyette lowered the firm’s price target on Crescent Capital BDC (CCAP) to $13 from $15 and keeps an Outperform rating on the shares.
Crescent Capital Group Closes Largest Fund in Firm's History with Fourth U.S. Direct Lending Fund, Raising $10.8 Billion in Investable Capital
LOS ANGELES & NEW YORK & BOSTON & CHICAGO--(BUSINESS WIRE)--Crescent Capital Group LP (“Crescent”), one of the leading alternative credit investment firms, announced today the successful final close o...
Crescent Capital BDC price target lowered to $13 from $15 at BofA
BofA analyst Derek Hewett lowered the firm’s price target on Crescent Capital BDC (CCAP) to $13 from $15 and keeps a Buy rating on the shares. The firm is adjusting…
Crescent Capital BDC Transcript: AGM 2026
The meeting confirmed quorum and proceeded with the election of two directors for terms expiring in 2029 and ratified Ernst & Young LLP as auditor for 2026. No shareholder questions were submitted during the session.
Crescent Capital BDC reduced fees a positive, says B. Riley
B. Riley keeps a Neutral rating on Crescent Capital BDC (CCAP) with a $13.50 price target following the “mixed” Q1 report. The biggest positive of the quarter is Crescent management…
Crescent Capital BDC price target lowered to $15 from $16 at Ladenburg
Ladenburg analyst Christopher Nolan lowered the firm’s price target on Crescent Capital BDC (CCAP) to $15 from $16 and keeps a Buy rating on the shares.
Crescent Capital BDC price target lowered to $12 from $13 at Wells Fargo
Wells Fargo analyst Finian O’Shea lowered the firm’s price target on Crescent Capital BDC (CCAP) to $12 from $13 and keeps an Equal Weight rating on the shares. The new…
Crescent Capital BDC downgraded to Perform from Outperform at Oppenheimer
Oppenheimer last night downgraded Crescent Capital BDC (CCAP) to Perform from Outperform with a price target of $16, down from $19. The firm increased Crescent’s equity discount rate by 50…
Crescent Capital BDC downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Crescent Capital BDC (CCAP) to Perform from Outperform with a price target of $16, down from $19.
Crescent Capital BDC Earnings Call Transcript: Q1 2026
NAV and NII declined due to increased non-accruals, especially in healthcare, but portfolio risk ratings remain stable. Management and incentive fees were reduced, the base dividend was reset, and Sun Life completed its acquisition of Crescent Capital.
Crescent Capital BDC Quarterly report: Q1 2026
Crescent Capital BDC has published its Q1 2026 quarterly earnings report on May 14, 2026.
Crescent Capital BDC Earnings release: Q1 2026
Crescent Capital BDC released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Crescent Capital BDC Slides: Q1 2026
Crescent Capital BDC has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.
Crescent Capital BDC declares 34c quarterly dividend, 9c special dividend
The company announced that its board of directors declared a second quarter regular cash dividend of 34c per share to stockholders of record as of June 30, payable on July…
Crescent Capital BDC reports Q1 EPS 42c, consensus 41c
Reports Q1 NAV per share $18.27. The company said, “Subsequent to quarter end, the Company reduced its fee structure, lowering its base management fee from 1.25% to 1.00% and its…
Crescent Capital BDC, Inc. Reports First Quarter 2026 Earnings Results; Declares a Second Quarter Base Dividend of $0.34 Per Share and Series of Special Dividends
LOS ANGELES, May 13, 2026 (GLOBE NEWSWIRE) -- Crescent Capital BDC, Inc. (“Crescent BDC” or the “Company”) (NASDAQ: CCAP) today reported net investment income of $0.42 per share and net income of ($0....
Crescent Capital BDC, Inc. Schedules Earnings Release and Conference Call to Discuss its First Quarter Ended March 31, 2026 Financial Results
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- Crescent Capital BDC, Inc. (“Crescent BDC”) (NASDAQ: CCAP) today announced it will release its financial results for the first quarter ended March 31, 2...
Crescent Capital BDC price target lowered to $15 from $15.50 at Keefe Bruyette
Keefe Bruyette analyst Paul Johnson lowered the firm’s price target on Crescent Capital BDC (CCAP) to $15 from $15.50 and keeps an Outperform rating on the shares. Published first on…
Crescent Capital BDC Proxy statement: Proxy filing
Crescent Capital BDC filed a proxy statement on April 1, 2026, providing details for shareholder voting and corporate governance matters.
Crescent Capital BDC Proxy statement: Proxy filing
Crescent Capital BDC filed a proxy statement on April 1, 2026, providing details for shareholder voting and corporate governance matters.
Crescent Capital BDC initiated with a Neutral at B. Riley
B. Riley initiated coverage of Crescent Capital BDC (CCAP) with a Neutral rating and $13.50 price target Crescent has historically compared favorably to the business development company sector on cred...
Crescent Capital BDC price target lowered to $13 from $14 at Wells Fargo
Wells Fargo analyst Finian O’Shea lowered the firm’s price target on Crescent Capital BDC (CCAP) to $13 from $14 and keeps an Equal Weight rating on the shares. The firm…
Crescent Capital BDC Earnings Call Transcript: Q4 2025
Q4 2025 net investment income was $0.45 per share, covering the dividend, with NAV per share declining to $19.10 due to unrealized losses. Portfolio remains diversified and first lien-focused, while management reviews dividend and fee structure amid lower rates.
Crescent Capital BDC Annual report: Q4 2025
Crescent Capital BDC has published its Q4 2025 annual report on February 26, 2026.